CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
about
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasSpotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma.Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.CAR T-cell therapy: opportunities and challenges.Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer.EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma.The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
P2860
Q26749139-A0E9890E-710F-4DEF-B0E7-628701CA2544Q38786626-09F53A05-A72C-49F8-8629-62535090EE3BQ39106490-A8A45A85-9485-4ECC-A181-4CB363547ED6Q46018826-B41EACED-B7DC-43D1-BD55-44AA4D3D08E3Q47793288-632CBAAF-F988-45AC-9B20-6A51DF264500Q48255324-3E827E5E-2972-4BB8-998A-9E5CFA3AA76FQ49280922-DBE47F30-D4EF-4F04-B6EE-D82D8AA35C4DQ49363296-2BAAE76E-8BD4-471D-BE6D-CE7AE4B50DC5Q50043438-3F1CB859-132F-4281-960D-080DC1C03C55Q55258890-90559D3C-0425-40E4-B54E-A202B2F5E261Q55689740-2B9EFACB-1235-49CA-A474-5FCF65E1CC33Q57177485-74F25060-0107-4FBE-AC22-B0AAC45A32C8
P2860
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@ast
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@en
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@nl
type
label
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@ast
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@en
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@nl
prefLabel
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@ast
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@en
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@nl
P2093
P2860
P356
P1433
P1476
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
@en
P2093
Angelica S I Loskog
Gunilla Enblad
Hannah Karlsson
P2860
P304
P356
10.1089/HUM.2015.054
P407
P577
2015-08-01T00:00:00Z